76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Haleon PLC
Closed
SectorHealthcare
377.6 -1.18
Overview
Share price change
24h
Min
376.7
Max
383.5
Income | -254M 231M |
|---|---|
Sales | -21M 2.8B |
P/E Sector Avg | 24 50.291 |
EPS | 0.042 |
Dividend yield | 1.72 |
Profit margin | 8.373 |
Employees | 24,561 |
EBITDA | -317M 399M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +16.2% upside |
Dividend yield Sector Avg | 1.72% 2.40% |
|---|---|
Next Earnings | 31 Jul 2025 |
Next Dividend date | 18 Sept 2025 |
Next Ex Dividend date | 14 Aug 2025 |
Market Cap | 478M 35B |
|---|---|
Previous open | 378.78 |
Previous close | 377.6 |
News Sentiment
By Acuity
50%
50%
102 / 380 Healthcare
Haleon PLC Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Haleon PLC Forecast
Price Target
By TipRanks
16.2% upside
12 Months Forecast
Average 444.83 GBX 16.2%
High 503 GBX
Low 360 GBX
Based on 12 Wall Street analysts offering 12 month price targets forHaleon PLC - Dist in the last 3 months.
Sentiment
By Acuity
102 / 380 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Haleon PLC
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
